Beyond Borders 2014 – Overview of the Biotechnology Landscape

Authors

  • Jürg Zürcher Ernst & Young AG Rain 41 CH-5001 Aarau, Switzerland. juerg.zuercher@ch.ey.com

DOI:

https://doi.org/10.2533/chimia.2014.840

Keywords:

Biotechnology, Business angels, Life sciences, Medical technology, Venture capital

Abstract

The global biotechnology industry rebounded strongly in 2013. Public companies achieved double-digit revenue growth and there was a sharp rise in funds. Product successes have boosted revenues, drawn investors and motivated large companies to invest strongly in R&D. However, much of the industry's growth was driven by a relatively small group of commercial stage companies, increasing the urgency for the rest of the industry to achieve greater efficiency in their drug development efforts.

Downloads

Published

2014-12-17

How to Cite

[1]
J. Zürcher, Chimia 2014, 68, 840, DOI: 10.2533/chimia.2014.840.